Direkt zum Inhalt
Merck

SAB4300137

Sigma-Aldrich

Anti-phospho-PRKDC (pThr2609) antibody produced in rabbit

affinity isolated antibody

Synonym(e):

Anti-DNA-PKcs antibody produced in rabbit, Anti-DNAPK antibody produced in rabbit, Anti-DNPK1 antibody produced in rabbit, Anti-HYRC antibody produced in rabbit, Anti-protein kinase, DNA-activated, catalytic polypeptide antibody produced in rabbit

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

MDL-Nummer:
UNSPSC-Code:
12352203
NACRES:
NA.41
Konjugat:
unconjugated
application:
WB
Klon:
polyclonal
Speziesreaktivität:
human
citations:
4
Methode(n):
western blot: 1:500-1:1000

Biologische Quelle

rabbit

Qualitätsniveau

Konjugat

unconjugated

Antikörperform

affinity isolated antibody

Antikörper-Produkttyp

primary antibodies

Klon

polyclonal

Form

buffered aqueous solution

Mol-Gew.

~450 kDa

Speziesreaktivität

human

Konzentration

1 mg/mL

Methode(n)

western blot: 1:500-1:1000

Isotyp

IgG

Immunogene Sequenz

(V-E-TP-Q-A)

NCBI-Hinterlegungsnummer

UniProt-Hinterlegungsnummer

Versandbedingung

wet ice

Lagertemp.

−20°C

Posttranslationale Modifikation Target

phosphorylation (pThr2609)

Angaben zum Gen

human ... PRKDC(5591)

Immunogen

Peptide sequence around phosphorylation site of threonine 2609 (V-E-T(p)-Q-A), according to the protein PRKDC.

Leistungsmerkmale und Vorteile

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

Zielbeschreibung

The PRKDC gene encodes the catalytic subunit of a nuclear DNA-dependent serine/threonine protein kinase (DNA-PK). The second component is the autoimmune antigen Ku (MIM 152690), which is encoded by the G22P1 gene on chromosome 22q. On its own, the catalytic subunit of DNA-PK is inactive and relies on the G22P1 component to direct it to the DNA and trigger its kinase activity; PRKDC must be bound to DNA to express its catalytic properties.

Physikalische Form

Solution in phosphate-buffered saline containing 0.02% sodium azide and 50% glycerol

Haftungsausschluss

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Sie haben nicht das passende Produkt gefunden?  

Probieren Sie unser Produkt-Auswahlhilfe. aus.

Lagerklassenschlüssel

10 - Combustible liquids

WGK

WGK 1

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable


Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Jessica A Neal et al.
DNA repair, 73, 7-16 (2018-11-10)
DNA-PKcs deficiency has been studied in numerous animal models and cell culture systems. In previous studies of kinase inactivating mutations in cell culture systems, ablation of DNA-PK's catalytic activity results in a cell phenotype that is virtually indistinguishable from that
Huanrong Ma et al.
International journal of cancer, 142(12), 2578-2588 (2018-01-25)
Cetuximab resistance is a key barrier in treating metastatic colorectal cancer (mCRC). Targeting of metabolic resources import could resensitize drug-resistant cancer cells to anticancer treatments. Here we showed that the expression of the glutamine transporter solute carrier 1 family member
Changhoon Choi et al.
PloS one, 14(6), e0218049-e0218049 (2019-06-14)
Recent studies have highlighted the implications of genetic variations in the relative biological effectiveness (RBE) of proton beam irradiation over conventional X-ray irradiation. Proton beam radiotherapy is a reasonable radiotherapy option for hepatocellular carcinoma (HCC), but the impact of genetic
Sissel Hauge et al.
Cell cycle (Georgetown, Tex.), 18(8), 834-847 (2019-04-05)
The Wee1 inhibitor MK1775 (AZD1775) is currently being tested in clinical trials for cancer treatment. Here, we show that the p53 target and CDK inhibitor p21 protects against MK1775-induced DNA damage during S-phase. Cancer and normal cells deficient for p21

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.